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Abstract
Background: Elacestrant is an oral selective estrogen receptor (ER) degrader. This phase 1b open-label, non-
randomized study (RAD1901-106) was initiated to determine the effect of elacestrant on the availability of ER in
lesions from postmenopausal women with ER+ advanced breast cancer (ABC) using 16α-18F-fluoro-17β-estradiol
positron emission tomography with low-dose computed tomography (FES-PET/CT).
Methods: Eligible patients were postmenopausal women with ER+, HER2− ABC; tumor progression after ≥ 6
months of 1–3 lines of endocrine treatment for ABC; and measurable or evaluable disease. Two 8-patient cohorts
were enrolled: one treated with 400 mg elacestrant once daily (QD) and one treated with 200 mg elacestrant QD
with dose escalation to 400 mg QD after 14 days. Elacestrant was dosed continuously until progressive disease,
toxicity, or withdrawal. FES-PET/CT was performed pre-dose at baseline and 4 h post-dose on day 14. The primary
endpoint was the percentage difference in FES uptake in tumor lesions (maximum 20) after 14 days of treatment
compared to baseline. Overall response was investigator-assessed by Response Evaluation Criteria in Solid Tumors
[RECIST] version 1.1.
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Results: Patients (n = 16; median age, 53.5 years) had ABC with a median 2.5 prior lines of endocrine therapy. Median
reduction in tumor FES uptake from baseline to day 14 was 89.1% (Q1, Q3: 75.1%, 94.1%) and was similar in both
cohorts (89.1% [Q1, Q3: 67.4%, 94.2%], 200/400mg and 88.7% [Q1, Q3: 79.5%, 94.1%], 400mg). Residual ER availability
(> 25% persistence in FES uptake) on day 14 was observed in 3 patients receiving 200/400mg (3/78, 37.5%) and 1
patient receiving 400mg (1/8, 12.5%). The overall response rate (ORR) was 11.1% (1 partial response), and clinical
benefit rate (CBR) was 30.8%. Median percentage change in FES uptake did not correlate with ORR or CBR. Adverse
events occurring in > 20% of the patients were nausea (68.8%), fatigue (50.0%), dyspepsia (43.8%), vomiting (37.5%),
and decreased appetite, dysphagia, and hot flush (31.3% each). Most events were grade 2 in severity.
Conclusion: Elacestrant 200mg and 400mg QD greatly reduced ER availability measured by FES-PET/CT. In a heavily
pretreated population, elacestrant was associated with antitumor activity.
Trial registration: ClinicalTrials.gov, NCT02650817. Registered on 08 January 2016
Keywords: Advanced breast cancer, Elacestrant, Endocrine therapy, Estrogen receptor, 16α-18F-fluoro-17β-estradiol
(FES), Hormonal therapy, Metastatic breast cancer, Positron emission tomography (PET), RAD1901
Background
Hormone receptor-positive breast cancer accounts for
approximately 70 to 80% of breast cancers [1, 2] for
which endocrine treatment in both the adjuvant and
advanced settings is recommended [3–5]. Available
endocrine therapies decrease estrogen production
(aromatase inhibitors), antagonize the estrogen receptor
(ER) (selective estrogen receptor modulators [SERMs],
e.g., tamoxifen), or degrade the ER (selective estrogen re-
ceptor degraders [SERDs], e.g., fulvestrant). Fulvestrant
is the only approved SERD for the treatment of post-
menopausal women with hormone receptor-positive ad-
vanced breast cancer. Fulvestrant has demonstrated
valuable clinical benefit and prolonged progression-free
survival (PFS) compared to anastrozole [6]. However,
fulvestrant is limited by its pharmacokinetic (PK) properties
and intramuscular route of administration, underscoring
the need for novel ER antagonists that are efficacious and
provide a more favorable PK profile [7, 8].
16α-18F-fluoro-17β-estradiol positron emission tomog-
raphy (FES-PET) has been used in a variety of preclinical
and clinical studies to detect ER expression in breast
cancer. FES-PET is a non-invasive imaging modality that
can be used to assess ER status of a tumor, potentially
replacing tumor biopsy [9]. It can visualize ER occupa-
tion with SERMs and ER downregulation with SERDs
due to reduced uptake of the FES tracer and has the
potential to predict response based on the degree of
downregulation [10–13]. A reduction of ≥ 75% was
reported to be associated with a longer PFS in patients
receiving fulvestrant compared to patients with a lower
reduction in FES uptake (11.7 months vs 3.3 months,
respectively; P < 0.05) [14].
Elacestrant is an investigational, nonsteroidal, oral
SERD. In ER+ breast cancer cell lines, elacestrant
showed dose-dependent ER degradation and inhibited
estradiol-dependent induction of ER target gene
transcription and cell proliferation [7, 8, 15]. In patient-
derived xenograft models of heavily pretreated patients
and in the ER+ MCF-7 breast cancer cell line xenograft
model, elacestrant inhibited estradiol-activated tumor
growth [7, 8, 15]. Elacestrant has also demonstrated antitu-
mor activity in breast cancer models harboring mutations
in estrogen receptor alpha gene (ESR1) known to confer re-
sistance (e.g., Y537S, D538G) and those resistant to cyclin-
dependent kinase 4,6 (CDK4/6) inhibitors [7, 16, 17].
In the clinical setting, elacestrant 400 mg daily has
demonstrated an objective response rate (ORR) of 19.4%
and median PFS of 4.5 months in a phase 1 trial
(RAD1901-005) of heavily pretreated postmenopausal
women with ER+/human epidermal growth factor recep-
tor (HER)2− advanced/metastatic breast cancer (ABC/
mBC) [18].
While the RAD1901-005 phase 1 trial was ongoing,
the current phase 1b study (RAD1901-106) was initiated
to determine the effect of elacestrant treatment on the
availability of ER in lesions from patients with ABC
using FES-PET with low-dose computed tomography
(FES-PET/CT) imaging as a measure of ER downregula-
tion. Additionally, the trial was designed to assess the
safety, preliminary efficacy, correlation of ER availability
with response, and PK of elacestrant in postmenopausal
women with ER+ ABC.
Methods
RAD1901-106 (NCT02650817) was a phase 1b, open-
label, non-randomized, multicenter, international study
conducted at 5 centers (3 in the Netherlands and 2 in
Belgium) between February 2016 and August 2018. The
study protocol and relevant supporting information were
approved by the institutional review board at each
participating site or by a national central review board.
The trial was performed in accordance with ethical prin-
ciples consistent with the Declaration of Helsinki and
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International Council of Harmonisation/Good Clinical
Practice and applicable regulatory requirements. Each
trial participant provided written informed consent.
The primary endpoint was the percentage difference in
FES uptake in tumor lesions (up to a maximum of 20
lesions) after 14 days of treatment with elacestrant com-
pared to baseline. Secondary endpoints were correlation
of changes in FES uptake after elacestrant treatment to
clinical responses measured by Response Evaluation
Criteria in Solid Tumors (RECIST) v1.1 [19], preliminary
antitumor effects of elacestrant, safety and tolerability of
elacestrant, and elacestrant PK. An exploratory endpoint
was correlation of tumor response with ESR1 mutations
detected in circulating tumor DNA (ctDNA).
Patients
Eligible patients were women ≥ 18 years of age who were
postmenopausal (defined as > 56 years old with amenorrhea
for > 12months, < 56 years old with amenorrhea for > 12
months plus serum estradiol < 20 pg/mL and follicle-
stimulating hormone > 40 mIU/mL, or prior bilateral ovari-
ectomy). Patients had histologically proven ER+ (defined as
≥ 1% staining by immunohistochemistry [20]), HER2− ABC
(either inoperable primary breast cancer or mBC); tumor
progression after ≥ 6months of 1–3 lines of systemic endo-
crine treatment for mBC; measurable disease according to
RECIST v1.1 or evaluable disease; Eastern Cooperative
Oncology Group (ECOG) performance status (PS) 0–2; life
expectancy > 3months; and adequate organ function. Prior
CDK4/6 inhibitor therapy was allowed.
Exclusion criteria included liver-only metastases (due
to high physiological liver uptake of FES, liver metastases
are not evaluable by FES-PET/CT imaging); untreated or
symptomatic central nervous system metastases; and
prior treatment with tamoxifen or fulvestrant therapy <
42 days before first FES-PET/CT scan (since these agents
may influence ER occupancy), other anticancer endo-
crine therapy < 14 days before first elacestrant dose, or
chemotherapy < 28 days before first elacestrant dose. Full
eligibility criteria are listed in an Additional file.
Study procedures
The study consisted of a screening period of up to 21
days prior to the first dose of elacestrant (with the ex-
ception of tumor imaging tests, which were performed
within 28 days of the first elacestrant dose); an open-
label treatment period; and a follow-up period during
which patients were followed for adverse events (AEs)
and concomitant medication use for 30 days after the
final dose of elacestrant or until resolution/stabilization
of all AEs to grade ≤ 2.
A total of 8 patients were initially enrolled and treated
with 400 mg elacestrant capsule once daily (QD)—the
recommended phase 2 dose determined in study
RAD1901-005. Following a protocol amendment, a sec-
ond cohort of 8 patients was enrolled and treated with
200 mg elacestrant capsule QD for 14 days to assess tar-
get engagement of a lower dose that might be utilized
when the 400-mg dose could not be tolerated alone or if
elacestrant was given in combination with another agent.
After 14 days, the dose was escalated to 400 mg QD.
Elacestrant was dosed continuously with 28-day treat-
ment cycles until progressive disease [PD], unacceptable
toxicity, or patient/investigator decision to withdraw.
Patients were instructed to take elacestrant at approxi-
mately the same time each day, approximately 30 min
after a light meal; to fast for ≥ 1 h after dosing; and to
remain upright for ≥ 2 h after taking elacestrant. After
the first 14 days of treatment, dosing delays of ≤ 7 days
were permitted. During the study, no hormonal medica-
tions, anticancer therapy, palliative radiotherapy, or
strong CYP3A inducers or inhibitors were permitted.
Assessments
At baseline, day 14 and day 28 of each cycle, and at end
of treatment, patients underwent physical examination,
ECOG PS assessment, and hematology and chemistry
laboratory evaluations. Patients also underwent 12-lead
electrocardiogram and coagulation evaluations at these
time points, except day 14. Transvaginal ultrasound was
performed at screening and end of treatment.
FES-PET/CT imaging
Imaging with FES-PET/CT was performed pre-dose at
baseline and approximately 4 h post-dose (Tmax) on day
14 of cycle 1. Patients were given a single bolus injection
of ~ 200MBq FES prior to whole-body PET/CT imaging.
Scan routines were conducted according to the European
protocol for standardization of 18F whole-body PET
studies, and quantification was performed using European
Association of Nuclear Medicine (EANM) Research Ltd.
(EARL) reconstruction according to the European stand-
ard for multicenter trials, as described in an Additional file
[21, 22]. The percentage difference in background-
corrected FES uptake in tumor lesions (up to an arbitrary
maximum of 20 lesions) after 14 days of treatment with
elacestrant compared to baseline was calculated. A relative
decrease of < 75% in the median (background-corrected)
tumor FES uptake and an absolute tumor lesion standard-
ized uptake value (SUV)max ≥ 1.5 was defined as incom-
plete reduction in ER availability.
ESR1 mutation analysis
Blood samples were collected for circulating tumor
DNA (ctDNA) analysis at screening, day 28 of cycles 1–
3, and at the end of treatment. The OncoBEAM™ assay
(Sysmex Inostics, Baltimore, MD) was used to determine
ESR1 mutational status in ctDNA. This is a digital
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droplet PCR (ddPCR) assay that detects 12 mutations in
the ligand binding domain of ESR1 (E380Q, S463P,
V524E, P535H, L536H/P/Q/R, Y537C/N/S, D538G) [23].
Pharmacokinetic analysis
Blood samples were collected for PK analysis at baseline
(pre-dose and 4 h post-dose), pre-dose on day 14 of
cycle 1, and day 28 of cycles 1–3. Elacestrant plasma
concentrations were determined using a validated ultra-
performance liquid chromatography with tandem mass
spectrometric detection method with a linear range of
0.05 to 100 ng/mL and a lower limit of quantification of
0.05 ng/mL (PRA Health Sciences, Assen, The Netherlands).
Tumor assessments
Tumor assessments were performed at screening, every
2 cycles, and end of treatment. Response was evaluated
by the investigator using RECIST v1.1. Clinical benefit
rates (CBR) at 16 weeks and 24 weeks were defined as
the proportion of patients who had confirmed CR or PR
any time during the study, or stable disease (SD) that
lasted at least 16 and 24 weeks, respectively.
Safety assessments
Adverse events were collected throughout the study up
to 30 days following the final elacestrant dose. The Med-
ical Dictionary for Regulatory Activities version 17.1 was
used for coding AEs, and the National Cancer Institute
Common Terminology Criteria for Adverse Events ver-
sion 4.03 was used to grade AE severity.
Statistical methods
The study planned to enroll a total of 16 patients (8 per
cohort). Percentage change in median FES uptake be-
tween baseline and day 14 was summarized as median
and interquartile range due to slightly skewed data for
each dose cohort and the overall population.
The intention-to-treat (ITT) population included all
patients who received at least 1 full or partial dose of
elacestrant. Best overall response was calculated for the
response evaluable population, which included all pa-
tients who had measurable disease at baseline and at
least 1 post-baseline RECIST assessment on any lesions
(target or nontarget) and/or had a new lesion. Best
overall response was summarized by dose cohort and
reported as percentage with the 2-sided 95% exact confi-
dence interval (CI) using the Clopper-Pearson method.
The CBR was calculated for the clinical benefit evaluable
population, which included all patients who had measur-
able and/or evaluable disease at baseline and at least 1
RECIST assessment post-baseline on any lesion (target
or nontarget) and/or had a new lesion. Clinical benefit
rate was summarized by dose cohort along with the 95%
CI. Correlation between the median percentage change
in FES uptake and best overall response was evaluated
using the Spearman’s rank correlation coefficient.
Kaplan-Meier methods were used to analyze PFS.
Elacestrant plasma concentrations were summarized
over time for each dose cohort. Adverse events and
changes in vital signs, laboratory tests, and ECGs were
summarized descriptively.
Results
A total of 16 patients were enrolled and all patients
received at least 1 dose of elacestrant and had paired
baseline and day 14 FES-PET imaging. All patients have
discontinued treatment, 12 (75.0%) due to radiographic
or clinical disease progression, 3 (18.8%) due to an
adverse event, and 1 (6.3%) for a protocol violation (treat-
ment interruption > 7 days) (Additional file Fig. S1). Base-
line characteristics were similar between the 2 dose
cohorts (Table 1). The median age was 53.5 (range 43–84)
years. All patients had ABC with a median number of
prior lines of endocrine therapy of 2.5; no patients had
prior CDK4/6 inhibitor therapy. Nine patients (56.3%) had
ESR1 mutation detected by ctDNA at baseline (D538G,
n = 6; Y537S, n = 5; Y537C, n = 2; Y537N, n = 2; E380Q,
n = 1; L536P, n = 1).
FES tumor uptake
Percentage change from baseline in tumor FES uptake
was assessed in all 16 patients. The median reduction in
tumor FES uptake from baseline to day 14 was 89.1%
(Q1, Q3: 75.1%, 94.1%; Table 2). Median reduction in
FES uptake was similar in both dose cohorts (89.1% [Q1,
Q3: 67.6%, 94.2%] in the 200/400mg cohort and 88.7%
[Q1, Q3: 79.5%, 94.1%] in the 400 mg cohort). The re-
duction in FES uptake was independent of baseline
ctDNA ESR1 mutation status (median reduction in FES
uptake 90.2% [Q1, Q3: 80.2%, 96.4%] in patients with
ESR1 mutation and 86.3% [Q1, Q3: 71.3%, 91.2%] in
patients without ESR1 mutation). A representative pre-
and post-elacestrant FES-PET scan in a patient with
extensive metastases is shown in Fig. 1. Residual ER
availability (defined as > 25% persistence in FES uptake)
was observed in 1 patient in the 400-mg elacestrant
cohort (1/8, 12.5%) and 3 patients in the 200/400-mg
elacestrant cohort (3/8, 37.5%; Fig. 2). Among 9 patients
with baseline ESR1 mutation, 8 had at least 1 post-
baseline ESR1 result. Among these 8 patients, 5 had
reduction in mutation allele frequency and 3 did not.
There was no difference between percent change in FES
uptake between the 2 groups (P > 0.05 calculated using
the Wilcoxon rank sum test).
Antitumor efficacy
The ORR was 11.1% (Table 3); of 9 patients evaluable
for overall response, 1 partial response was observed (in
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a patient without an ESR1 mutation); the time to re-
sponse was 7.9 weeks and the duration of response was
22 weeks. The CBR was 30.8%; 4 out of 13 patients eva-
luable for CBR had stable disease at 24 weeks. Of these 4
patients, 1 had an ESR1 mutation. No significant correl-
ation was found between the median percentage change
in FES uptake and best overall response (Spearman’s
rank correlation coefficient − 0.13; P > 0.7). The patient
who experienced a partial response had a 78.9% reduc-
tion in FES uptake. In the ITT population, median PFS
was 5.3 months (95% CI, 1.7, 17.9).
Pharmacokinetics of elacestrant
Pharmacokinetics were evaluated in all 16 patients. Over
the first 2 weeks of treatment, the geometric mean ela-
cestrant plasma concentrations were approximately
twice as high for patients receiving 400 mg QD as those
for patients receiving 200 mg QD (59.8 ng/mL vs 27.4
ng/mL at cycle 1, day 1, hour 4 post-dose, respectively,
and 70.1 ng/mL versus 20.1 ng/mL at cycle 1, day 14,
pre-dose, respectively; Fig. 3). Elacestrant plasma con-
centrations at additional timepoints are summarized in
Additional file Table S1.
Table 1 Demographics and baseline characteristics
Characteristic Elacestrant dose cohort
200/400mg (N = 8) 400 mg (N = 8) Overall (N = 16)
Median age (range), years 57.0 (49, 74) 53.0 (43, 84) 53.5 (43, 84)
Female, n (%) 8 (100) 8 (100) 16 (100)
ECOG performance status, n (%)
0 3 (37.5) 3 (37.5) 6 (37.5)
1 5 (62.5) 4 (50.0) 9 (56.3)
2 0 1 (12.5) 1 (6.3)
Ductal carcinoma, n (%) 8 (100) 8 (100) 16 (100)
Median time since breast cancer
diagnosis (Q1, Q3), yearsa
12.5 (5.8, 16.7) 6.0 (4.2, 11.0) 8.5 (5.2, 13.7)
Stage IV, n (%) 8 (100) 8 (100) 16 (100)
Visceral diseaseb, n (%) 5 (62.5) 5 (62.5) 10 (62.5)
Bone-only disease, n (%) 1 (12.5) 1 (12.5) 2 (12.5)
ESR1 mutationc, n (%) 4 (50.0) 5 (62.5) 9 (56.3)
Median number of lines of prior
anticancer therapy (Q1, Q3), n
Total, for ABC 3.0 (1.5, 3.0) 3.0 (2.0, 3.0) 3.0 (2.0, 3.0)
Endocrine therapy, for ABC 3.0 (1.5, 3.0) 2.0 (2.0, 3.0) 2.5 (2.0, 3.0)
Chemotherapy, for ABC 0 (0, 1.0) 0.5 (0, 1.0) 0 (0, 1.0)
Adjuvant endocrine therapy, n (%) 7 (87.5) 6 (75.0) 13 (81.3)
Prior fulvestrant, n (%) 4 (50.0) 2 (25.0) 6 (37.5)
Prior mTOR inhibitor, n (%) 3 (37.5) 3 (37.5) 6 (37.5)
Prior CDK4/6 inhibitor, n (%) 0 0 0
CDK4/6, cyclin-dependent kinase 4,6; ECOG, Eastern Cooperative Oncology Group; mTOR, mammalian target of rapamycin
aMedian time since breast cancer diagnosis regardless of stage
bIncludes the liver, lung, and pleura
cMutations detected include D538G (n = 6), Y537S (n = 5), Y537C (n = 2), Y537N (n = 2), E380Q (n = 1), and L536P (n = 1)
Table 2 Percentage change in FES uptake from baseline to day 14 for the two different dose cohorts
Elacestrant dose cohort
Parameter 200/400mg (N = 8) 400 mg (N = 8) Overall (N = 16)
Number evaluated, n (%) 8 (100)a 8 (100) 16 (100)
Mean (SD), % − 82.6 (15.5) − 86.0 (10.2) − 84.3 (12.8)
Median (Q1, Q3), % − 89.1 (− 94.2, − 67.6) − 88.7 (− 94.1, − 79.5) − 89.1 (− 94.1, − 75.1)
ITT intention to treat, FES 16α-18F-fluoro-17β-estradiol
aOne patient who had < − 100% change (i.e., > 100% reduction) was included as − 100%
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Safety
The median duration of elacestrant treatment was 4.3
months (range, 0.4–23.2). Patients in the 400-mg cohort
remained on treatment longer than the 200/400-mg co-
hort (median 5.2 months [range, 0.7–23.2] vs 1.8 [range,
0.4–18.1] months, respectively). One patient receiving
the initial dose of 200 mg did not dose escalate to 400
mg per protocol due to a serious AE of grade 3 esopha-
gitis that was assessed as possibly related to elacestrant
by the investigator and that resulted in treatment dis-
continuation. Two additional patients discontinued
treatment due to AEs: grade 2 nausea, fatigue, and an-
orexia in 1 patient, and grade 2 cough and grade 1 upper
extremity peripheral edema in 1 patient. Among all pa-
tients, 4 (25.0%) had dose delay and 2 (12.5%) had dose
reduction due to a treatment-emergent AE (TEAE). All
patients experienced at least 1 TEAE (Table 4). The
most common TEAEs occurring in > 20% of patients
were nausea (n = 11, 68.8%), fatigue (n = 8, 50.0%), dys-
pepsia (n = 7, 43.8%), vomiting (n = 6, 37.5%), decreased
appetite, dysphagia, and hot flush (n = 5, 31.3% each;
Table 4). The majority of patients (n = 10, 62.5%) had
grade 2 TEAEs. Five grade 3 TEAEs occurred in 4 pa-
tients; no grade 4 or 5 events occurred (Table 5).
Adverse events assessed as related to elacestrant by the
investigator occurred in 15 patients (93.8%), with gastro-
intestinal disorders being the most commonly reported.
Fig. 1 Reduction in FES uptake after elacestrant treatment in a
patient with ESR1 mutation. Images depict FES-PET scan in the
patient at baseline (left) and 14 days after receiving elacestrant 400
mg daily (right), at which time a 96.6% reduction in FES uptake was
observed. Physiologic FES uptake/excretion is observed in the liver,
intestines, bladder, and port-a-cath infusion line; pathologic uptake is
observed in bone lesions and lymph nodes
Fig. 2 Percentage change from baseline to day 14 in median FES uptake for individual patients in the intention-to-treat population. One patient
who had < − 100% change (i.e., > 100% reduction) was included as −100%. Response per RECIST (PR, SD, PD, NE) for each patient and patients
with CBR at 24 weeks (†) are noted. FES, 16α-18F-fluoro-17β-estradiol
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No consistent trends were observed in clinically signifi-
cant changes in laboratory parameters, vital signs, or
electrocardiogram parameters.
Discussion
In the current study, the investigational oral SERD elaces-
trant decreased ER availability for binding 17β-estradiol to
tumor metastases (assessed by reduction in FES uptake
quantified using FES-PET/CT imaging) by a median of
89%, with 12 of 16 patients demonstrating a reduction of
≥ 75%. A reduction of ≥ 75% is suggested to be clinically
relevant since this cut-off was found to be associated with
a longer PFS in patients receiving fulvestrant compared to
patients with a lower reduction in FES uptake [14].
In our phase 1 study, the proportion of patients with
a ≥ 75% reduction in ER availability was 62.5% in the co-
hort receiving a dose of 200 mg elacestrant QD and 88%
in the cohort receiving the recommended phase 2 dose
(RP2D) of 400mg QD. These proportions appear to be
similar or higher than the 63% reported for treatment
with fulvestrant [14], suggesting an equivalent or better
reduction in ER availability by elacestrant at both the
Table 3 Efficacy endpoints in evaluable populations
Parameter Elacestrant dose cohort
200/400mg 400mg Overall
Response N = 4 N = 5 N = 9
ORR, % 0 20.0 11.1
Partial response, n (%) 0 1 (20.0) 1 (11.1)
Duration of response, weeks – 22 22
Time to response, weeks – 7.9 7.9
Stable disease, n (%) 2 (50.0) 3 (60.0) 5 (55.6)
Progressive disease, n (%) 2 (50.0) 1 (20.0) 3 (33.3)
CBR N = 6 N = 7 N = 13
16 weeks, n (%) 3 (50.0) 4 (57.1) 7 (53.8)
24 weeks, n (%) 1 (16.7) 3 (42.9) 4 (30.8)
Median PFS (95% CI), months 3.6 (0.7, 17.9) 6.9 (0.7, NA) 5.3 (1.7 17.9)
CBR clinical benefit rate, ORR objective response rate, PFS progression-free survival
Fig. 3 Geometric mean elacestrant plasma concentrations over time (N = 16). Vertical bars indicate standard error of the mean
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200 mg and 400 mg doses. While the proportion of
patients with a ≥ 75% reduction in ER availability with
the elacestrant 200 mg dose at day 14 was lower than
the 400mg RP2D dose, this lower reduction in FES up-
take should not lead to the conclusion that elacestrant
200 mg is not efficacious. It should also be noted that
the reduction in FES uptake for 200 mg elacestrant was
similar to what was reported for fulvestrant 500 mg at
day 28 [14]; therefore, these data suggest that elacestrant
200 mg may be a potential option for patients who re-
quire a dose reduction from the 400 mg RP2D due to
toxicity.
Patients enrolled in the current study were heavily pre-
treated (median 3 prior lines of therapy in all settings,
median 2.5 lines of endocrine therapy in the advanced
setting, 38% prior fulvestrant); however, none had prior
CDK4/6 inhibitor exposure. Moreover, 56% of the
patients had a detectable ESR1 mutation by ctDNA at
baseline, as is expected with extensive prior endocrine
therapy [24, 25]. Despite these unfavorable prognostic
characteristics, elacestrant demonstrated antitumor
activity with an ORR of 11% and a median duration of
response of 22 weeks. A 24-week CBR was observed in
31% of patients and the median PFS was 5.3 months.
There was no correlation between reduction in ER avail-
ability to treatment response; however, the sample size
evaluable for response in our study was too small to
draw any conclusions (n = 9 evaluable for tumor overall
response with 1 partial response). Other investigators
have observed a correlation between degree of ER
blockade on FES-PET and clinical response to tam-
oxifen and clinical benefit with fulvestrant [26, 27]. Deh-
dashti et al. reported a mean SUV decrease of 2.7 in
responders versus 0.8 in nonresponders (P = 0.04) in a
study of 11 women with newly diagnosed mBC [26]. Mor-
timer et al. reported a mean SUV decrease of 2.5 in re-
sponders versus 0.5 in nonresponders (P = 0.0003), which
corresponded to a mean percentage decrease in SUV of
54.8% in responders versus 19.4% in nonresponders (P =
0.0003), in 40 women with locally advanced, chest-wall re-
current, or mBC [27]. It should be noted that neither
study utilized RECIST criteria to define response or PET
image reconstruction according to EANM/EARL guide-
lines. EARL/EANM accreditation is recommended for
proper FES-PET implementation to avoid erroneous re-
sults [21, 22].
FES-PET scanning has not been routinely available at
clinical sites and has generally been reserved for
Table 4 Adverse events occuring in ≥ 10% of the ITT population
Adverse event (AE), n
(%)
Elacestrant dose cohort
200/400mg (N = 8) 400 mg (N = 8) Overall (N = 16)
At least 1 AE 8 (100) 8 (100) 16 (100)
Nausea 5 (62.5) 6 (75.0) 11 (68.8)
Fatigue 4 (50.0) 4 (50.0) 8 (50.0)
Dyspepsia 2 (25.0) 5 (62.5) 7 (43.8)
Vomiting 5 (62.5) 1 (12.5) 6 (37.5)
Decreased appetite 4 (50.0) 1 (12.5) 5 (31.3)
Dysphagia 1 (12.5) 4 (50.0) 5 (31.3)
Hot flush 2 (25.0) 3 (37.5) 5 (31.3)
Hypertension 0 3 (37.5) 3 (18.8)
Arthralgia 1 (12.5) 2 (25.0) 3 (18.8)
Dizziness 2 (25.0) 1 (12.5) 3 (18.8)
Dyspnea 0 3 (37.5) 3 (18.8)
Abdominal pain upper 2 (25.0) 1 (12.5) 3 (18.8)
Back pain 0 2 (25.0) 2 (12.5)
Diarrhea 1 (12.5) 1 (12.5) 2 (12.5)
Esophageal pain 1 (12.5) 1 (12.5) 2 (12.5)
Neck pain 1 (12.5) 1 (12.5) 2 (12.5)
Pain in extremity 1 (12.5) 1 (12.5) 2 (12.5)
Cough 1 (12.5) 1 (12.5) 2 (12.5)
Nail discoloration 1 (12.5) 1 (12.5) 2 (12.5)
Anemia 0 2 (25.0) 2 (12.5)
ITT intention to treat
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investigational purposes at select academic centers. As
more data become available from ongoing trials validat-
ing the safety and predictive accuracy of FES-PET im-
aging, it could replace or supplement tumor biopsy.
FES-PET allows the level and heterogeneity of ER ex-
pression across the full burden of disease to be evaluated
to help guide treatment selection and characterize dis-
tinct subsets of patients [9]. The noninvasiveness of
FES-PET could also facilitate serial imaging to monitor
effect of ER-targeted therapies on treatment; ineffective
agents could be switched earlier if reduction in ER avail-
ability is not observed. The first FES-PET imaging agent
specifically indicated for use in patients with recurrent
or metastatic breast cancer was approved by the FDA in
May 2020 [28]. Availability of this agent in the US may
lead to more widespread use for diagnostic purposes.
Strengths of this study are that ER target engagement
was assessed with robust FES-PET/CT imaging, which
allows whole-body visualization and quantification of ER
availability on ER-expressing metastases and has shown
predictive value for response on fulvestrant [12, 14]. The
imaging was performed at an EARL/EANM-accredited aca-
demic center that routinely uses this technology. This study
also assessed antitumor activity using the stringent RECIST
criteria to measure response. The sample size was relatively
modest for a phase 1 FES-PET/CT imaging study (only 8
patients were included per cohort), which limited the
study’s capability to evaluate the correlation between reduc-
tion in ER availability and treatment response.
Conclusions
This study demonstrated that elacestrant greatly re-
duces ER availability, as measured by FES-PET/CT im-
aging, at doses of 200 mg and 400 mg QD, to a similar,
if not better, extent than that reported for fulvestrant.
In a heavily pretreated population, including 56% of pa-
tients with ESR1 mutation, elacestrant was associated
with antitumor activity. The safety profile of elacestrant
was acceptable, consisting predominately of low-grade
upper gastrointestinal toxicity. The risk-benefit profile
supports further development of elacestrant in ER+/
HER2− ABC. This study supports the use of elacestrant
Table 5 Grade 3 adverse events, serious adverse events, and adverse events leading to discontinuation
Adverse event (AE), n (%) Elacestrant dose cohort
200/400mg (N = 8) 400 mg (N = 8) Overall (N = 16)
Grade 3 AEsa 1 (12.5) 3 (37.5) 4 (25.0)
Anemia 0 1 (12.5) 1 (6.3)
Circulatory collapse 0 1 (12.5) 1 (6.3)
Esophagitis 1 (12.5) 0 1 (6.3)
Cystitis 0 1 (12.5) 1 (6.3)
Pulmonary embolism 0 1 (12.5) 1 (6.3)
Serious AEs 1 (12.5) 2 (25.0) 3 (18.8)
Esophagitis 1 (12.5) 0 1 (6.3)
Amnesia 0 1 (12.5)b 1 (6.3)
Circulatory collapse 0 1 (12.5)b 1 (6.3)
Presyncope 0 1 (12.5)b 1 (6.3)
Pulmonary embolism 0 1 (12.5)c 1 (6.3)
Dyspnea 0 1 (12.5)c 1 (6.3)
AEs leading to elacestrant discontinuation 3 (37.5) 0 3 (18.8)
Esophagitis 1 (12.5) 0 1 (6.3)
Nausea 1 (12.5)d,e 0 1 (6.3)
Fatigue 1 (12.5)d,e 0 1 (6.3)
Anorexia 1 (12.5)d,e 0 1 (6.3)
Cough 1 (12.5)d,f 0 1 (6.3)
Upper extremity peripheral edema 1 (12.5)d,f 0 1 (6.3)
aThere were no grade 4 AEs
bThese events occurred in the same patient
cThese events occurred in the same patient
dThese events occurred during treatment with elacestrant 400 mg
eGrade 2 nausea, fatigue, and anorexia occurred in the same patient
fGrade 2 cough and grade 1 upper extremity peripheral edema occurred in the same patient
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400 mg as the recommended dose for future studies. A
randomized phase 3 study comparing elacestrant 400
mg to standard-of-care endocrine monotherapy (EMER
ALD: NCT03778931) in postmenopausal women and
men with ER+/HER2− ABC is currently ongoing.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13058-020-01333-3.
Additional file 1: Table S1. Elacestrant plasma concentrations over
time. Figure S1. Patient disposition.
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